Department for International Trade written question – answered at on 9 March 2020.
To ask the Secretary of State for International Trade, what assessment she has made of the potential merits of protecting regulatory data exclusivity for innovative drugs in a UK-US trade deal.
The Government’s objectives for US negotiations state that we will secure provisions that protect the UK’s world-leading intellectual property standards and seek an effective and balanced regime which supports innovation within the pharmaceutical sector, while reflecting wider public interests such as ensuring patient access to medicines.
The Government is clear that when negotiating free trade agreements, the NHS and the price the NHS pays for medicines will not be on the table. We will not agree to measures which undermine the Government’s ability to deliver our NHS manifesto commitments.
Yes1 person thinks so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.